High Incidence of Diseases
Invasive candidiasis is considered a common infection across the globe. The Center for Disease Control and Prevention (CDC) estimates that approximately 46,000 cases of healthcare-associated invasive candidiasis occur each year, in the United States. Most cases of invasive candidiasis are not associated with disease outbreaks. However, a few hospital-associated clusters linked to common sources have been documented. The market for systemic candidiasis is driven by an increase in the susceptible immune compromised patient pool. The high incidence of candidiasis is expected to remain a major driver for the growth of the market during the forecast period. Invasive Candida infections are often associated with high rates of incidence and mortality, as well as increases in cost and length of hospital stay. CDC reports that the 30-day all-cause (crude) mortality among people with candidemia is approximately 30%. However, as people who develop invasive candidiasis typically have pre-medical conditions, it is generally ambiguous to determine the proportion of deaths directly attributable to the infection.
Narrow Pipeline Molecules
High morbidity and mortality rates associated with candidiasis clearly indicate that current antifungal therapy to cure candidiasis is still ineffective. Unlike antibacterial antibiotics, the current arsenal of antifungal drugs is extremely limited and short. In addition, there are no new effective drugs in sight, and the number of antifungal products in the pipeline is quite less. Hence, no new antifungal drugs are expected to hit the market any time soon. The future looks even more pessimistic, as big players in the market, such as pharmaceutical companies, are increasingly focusing their efforts on drugs that treat chronic conditions typically associated with the sedentary lifestyle, at the expense of the much less ‘profitable’ antibiotics. The fact that fungal cells are eukaryotic makes antifungal drug development even more complicated. Therefore, it is much more difficult to identify selective pathogen-specific targets for drug discovery and development. Alarmingly, this is also the main reason for the raised toxicity of some of the current therapies. From a clinical point of view, the current options available to combat candidiasis are limited to three classes of antifungal agents - polyenes, azoles, and echinocandins. The availability of herbal alternative for the fungal infection may hamper the growth of the market.
North America to Dominate the Market
The market studied has been segmented by route of administration, drug type, anatomy type, distribution channel, and geography. By geography, it has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.
The Center for Disease Control and Prevention (CDC) reports that, in the United States, certain species of Candida are becoming increasingly resistant to available antifungals, such as azoles and approved echinocandins. Extensive usage of antifungals in the azole class has stimulated an increase in the number of strains of Candida that have a high rate of azole resistance. A recent US-based study found that the percentage of non-albicans Candida species increased from 46% in 2006 to 60% in 2011.
Major Players- BASILEA PHARMACEUTICALS, ASTELLAS, FERRER INTERNACIONAL, PACGEN BIOPHARMACEUTICALS, NOVADIGM THERAPEUTICS, PEVION BIOTECH, AMPLYX PHARMACEUTICALS INC., BIOMAR MICROBIAL TECHNOLOGIES, CIDARA THERAPEUTICS, NOVABIOTICS LIMITED, amongst others.
Reasons to Purchase this Report
- Analysis of the global candidiasis therapeutics market, with region-specific assessments and competition analysis on global and regional scales
- Analyzing various perspectives of the industry with the help of Porter’s five forces analysis
- The treatment type that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3 months analyst support along with the Market Estimate sheet (in excel)
This report can be customized to meet your requirements..
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Susceptible Immune Compromised Patient Pool
6.1.2 Growing Awareness for Candidiasis Infection
6.2 Market Restraints
6.2.1 Availability of Alternative Treatments
6.2.2 Narrow Pipeline Molecules
6.2.3 Competition from Herbal Medicines and Alternate Therapies
6.4 Key Challenges
7. Market Segmentation
7.1 By Route of Administration
7.2 By Drug Type
7.3 By Anatomy Type
7.3.1 Oral Candidiasis
7.3.2 Vulvovaginal Candidiasis
7.3.3 Cutaneous Candidiasis
7.3.4 Invasive Candidiasis
7.3.5 Systemic Candidiasis
7.4 By Distribution Channel
7.4.3 Retail Pharmacies
7.4.4 Drug Stores
7.5 By Geography
7.5.1 North America
184.108.40.206 Rest of Europe (RoE)
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
7.5.4 Middle East And Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East & Africa
188.8.131.52 South America
184.108.40.206 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Key Players
9.1 Basilea Pharmaceuticals
9.3 Ferrer Internacional
9.4 Pacgen Biopharmaceuticals
9.5 Novadigm Therapeutics
9.6 Amplyx Pharmaceuticals Inc.
9.7 Biomar Microbial Technologies
9.8 Cidara Therapeutics, Inc.
9.9 Novabiotics Limited
10. Future of the Market
- Basilea Pharmaceuticals
- Ferrer International
- Pacgen Biopharmaceuticals
- Novadigm Therapeutics
- Amplyx Pharmaceuticals Inc.
- Biomar Microbial Technologies
- Cidara Therapeutics Inc.
- Novabiotics Limited